Blood-Based Epigenetic Biomarkers Associated With Incident Chronic Kidney Disease in Individuals With Type 2 Diabetes
There is an increasing need for new biomarkers to improve the prediction and prevention of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D), a leading cause of morbidity and mortality in this population. We investigated whether new blood-based epigenetic biomarkers predict incident CKD in individuals with newly diagnosed T2D. We discovered a novel blood-based epigenetic biomarker, composed of a combination of a methylation risk score and clinical factors, capable of predicting CKD during an 11.5-year follow-up (area under the curve of 0.87, negative predictive value of 94.6%) in individuals with newly diagnosed T2D. The epigenetic biomarker could provide a valuable tool for early risk stratification and prevention of CKD in individuals with newly diagnosed T2D, supporting its future use for precision medicine.
Authors
- Alexander Perfilyev (ORCID: https://orcid.org/0000-0003-1136-8946)
- Alice Maguolo (ORCID: https://orcid.org/0000-0002-8921-2012)
- Marian Marchiori (ORCID: https://orcid.org/0000-0002-8849-1291)
- Marlena Maziarz (ORCID: https://orcid.org/0000-0003-1417-6050)
- Emma Ahlqvist (ORCID: https://orcid.org/0000-0002-6513-2384)
- Mats Martinell (ORCID: https://orcid.org/0000-0002-6060-6229)
- Charlotte Ling (ORCID: https://orcid.org/0000-0003-0587-7154)
- Maria F. Gomez (ORCID: https://orcid.org/0000-0001-6210-3142)
- Sonia García-Calzón (ORCID: https://orcid.org/0000-0002-1249-4795)
Institutions
- Uppsala University (SE)
- University of Southern Denmark (DK)
- Malmö University (SE)
- Lund University (SE)
- Instituto de Salud Carlos III (ES)
- Navarre Institute of Health Research (ES)
- Skåne University Hospital (SE)
- Universidad de Navarra (ES)
Publication Details
- Journal
- Diabetes
- Published
- 2024-12-23
- DOI
- https://doi.org/10.2337/db24-0483
- Citations
- 9
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 2.10
Funders
- European Federation of Pharmaceutical Industries and Associations
- European Commission
- Stiftelsen för Strategisk Forskning
- Lunds Universitet
- Novo Nordisk
- Vetenskapsrådet
- Novo Nordisk Fonden
- Skånes universitetssjukhus
- Horizon 2020 Framework Programme